Hematologic Malignancy
Lymphoid Neoplasm
CI-CAN-00009335Explore in graph →
Hematologic2,419 active trials60 approved drugs271 evidence items
- OncoTree
- LNM
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00009335Explore in graph →
Clinical trials
8,885 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,373)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07802717 | A Phase 1 Dose-escalation and Expansion Study of In Vivo BCMA-CAR T Cell Therapy (VV169) in Patients With Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 | 40 | Vyriad, Inc.INDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07830238 | SNC116 Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia | not yet recruiting | Early Phase 1 | 28 | Shanghai Simnova Biotechnology Co.,Ltd.INDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07830485 | CM336 Plus Daratumumab and Lenalidomide in Transplant-Ineligible Newly Diagnosed Multiple Myeloma(CAREMM-010) | not yet recruiting | Phase 2 | 24 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07831122 | Study of Belantamab Mafodotin, Cevostamab, Pomalidomide for RRMM Patients (MAPLE) | not yet recruiting | Phase 1 | 108 | Canadian Myeloma Research GroupOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT04439253 | Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G) | active not recruiting | Phase 2 | 4 | National Cancer Institute (NCI)NIH | 1 | Sep 18, 2026 | clinicaltrials |
| NCT04594798 | A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL | active not recruiting | Phase 2 | 39 | University of RochesterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT04752826 | BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20) | recruiting | Phase 1 / Phase 2 | 250 | BioInvent International ABINDUSTRY | 7 | Sep 18, 2026 | clinicaltrials |
| NCT04933539 | Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma | active not recruiting | Phase 2 | 14 | National Cancer Institute (NCI)NIH | 1 | Sep 18, 2026 | clinicaltrials |
| NCT05013190 | A Study of NINLARO® in Chinese Adults With Multiple Myeloma | active not recruiting | — | 72 | TakedaINDUSTRY | 1 | Sep 18, 2026 | clinicaltrials |
| NCT05025800 | ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma | active not recruiting | Phase 1 / Phase 2 | 47 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT05615636 | A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL | recruiting | Phase 2 | 36 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT05627245 | Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment | active not recruiting | Phase 1 | 48 | National Cancer Institute (NCI)NIH | 1 | Sep 18, 2026 | clinicaltrials |
| NCT06534437 | MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)(JASPIS-01) | recruiting | Phase 2 | 178 | Ryvu Therapeutics SAINDUSTRY | 4 | Sep 18, 2026 | clinicaltrials |
| NCT07210047 | Study of HuL001 in Relapsed/Refractory Multiple Myeloma Patients | recruiting | Phase 1 / Phase 2 | 21 | HuniLife Biotechnology, Inc.INDUSTRY | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07382739 | A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD" | recruiting | Phase 2 | 34 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07422610 | Pharmacokinetics and Safety Study of Pelabresib in Patients With Advanced Malignancies and Hepatic Impairment | recruiting | Phase 1 | 24 | Novartis PharmaceuticalsINDUSTRY | 4 | Sep 18, 2026 | clinicaltrials |
| NCT07809594 | CS1-Targeted CAR-T Cells for Relapsed/Refractory Multiple Myeloma(GZLTCST0001) | active not recruiting | Phase 1 | 10 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07828522 | F182112 in Combination With Isatuximab and Lenalidomide for the Treatment of Patients With Newly Diagnosed Multiple Myeloma(CAREMM-009) | not yet recruiting | Phase 2 | 10 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Sep 18, 2026 | clinicaltrials |
| NCT03672318 | Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma | active not recruiting | Phase 1 | 25 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT04071457 | S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration(DRAMMATIC) | active not recruiting | Phase 3 | 1,100 | SWOG Cancer Research NetworkNETWORK | 2 | Sep 17, 2026 | clinicaltrials |
| NCT04688151 | Rituximab, Acalabrutinib, and Durvalumab (RAD) in Primary CNS Lymphoma. | completed | Phase 1 | 22 | National Health Research Institutes, TaiwanOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT04879043 | Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 78 | Heidelberg Pharma AGINDUSTRY | 5 | Sep 17, 2026 | clinicaltrials |
| NCT04910568 | A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma(CAMMA 1) | recruiting | Phase 1 | 186 | Genentech, Inc.INDUSTRY | 13 | Sep 17, 2026 | clinicaltrials |
| NCT05827016 | A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma | active not recruiting | Phase 3 | 1,230 | Bristol-Myers SquibbINDUSTRY | 34 | Sep 17, 2026 | clinicaltrials |
| NCT06395103 | Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01) | recruiting | Phase 1 / Phase 2 | 90 | Merck Sharp & Dohme LLCINDUSTRY | 23 | Sep 17, 2026 | clinicaltrials |
| NCT07221500 | A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201) | recruiting | Phase 2 | 100 | Nurix Therapeutics, Inc.INDUSTRY | 5 | Sep 17, 2026 | clinicaltrials |
| NCT07223021 | A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia | recruiting | Phase 3 | 130 | Memorial Sloan Kettering Cancer CenterOTHER | 2 | Sep 17, 2026 | clinicaltrials |
| NCT07341191 | Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy | recruiting | Phase 2 | 40 | Canadian Cancer Trials GroupNETWORK | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07576725 | Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial | not yet recruiting | Phase 2 | 50 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07585760 | CM336 Plus Isatuximab for Newly Diagnosed Multiple Myeloma With Renal Impairment(CAREMM-012) | recruiting | Phase 2 | 26 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07623798 | A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003 | recruiting | Phase 3 | 255 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07760454 | A Clinical Study of CT0596 CAR-T in Relapsed/Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 68 | UCARsgen Biotech LimitedOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07823959 | CBC-Based Inflammatory Indices in Newly Diagnosed Multiple Myeloma | not yet recruiting | — | 60 | Assiut UniversityOTHER | 0 | Sep 17, 2026 | clinicaltrials |
| NCT07825064 | Cevostamab in Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR T-Cell Therapy in Participants With Previously Treated Multiple Myeloma | recruiting | Phase 2 | 45 | Hoffmann-La RocheINDUSTRY | 1 | Sep 17, 2026 | clinicaltrials |
| NCT00900198 | Collection of Tissue Samples for Cancer Research | recruiting | — | 5,000 | National Cancer Institute (NCI)NIH | 2 | Sep 16, 2026 | clinicaltrials |
| NCT01947140 | Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies(PDX+Romi) | terminated | Phase 1 / Phase 2 | 57 | Jennifer AmengualOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT02446236 | Dose Finding Study of Ibrutinib Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma | active not recruiting | Phase 1 | 27 | Hackensack Meridian HealthOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT02629809 | Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia | active not recruiting | Phase 2 | 81 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT03389347 | High Throughput Drug Sensitivity and Genomics Data in Developing Individualized Treatment in Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia | completed | N/A | 40 | University of WashingtonOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT04002947 | Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma | recruiting | Phase 2 | 132 | National Cancer Institute (NCI)NIH | 1 | Sep 16, 2026 | clinicaltrials |
| NCT04322383 | Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant | recruiting | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Sep 16, 2026 | clinicaltrials |
| NCT04462328 | Acalabrutinib and Durvalumab in Primary and Secondary Central Nervous System Lymphoma | active not recruiting | Phase 1 | 25 | Washington University School of MedicineOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT04635189 | Steroid Sparing Treatment With in Newly Diagnosed Transplant Ineligible Patients With Multiple Myeloma | active not recruiting | Phase 2 | 28 | University of RochesterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT04815356 | Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant | recruiting | Phase 1 | 27 | National Cancer Institute (NCI)NIH | 1 | Sep 16, 2026 | clinicaltrials |
| NCT04883242 | Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma | active not recruiting | Phase 2 | 30 | University of WashingtonOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT04938232 | Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL | active not recruiting | Phase 2 | 13 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT05283993 | A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH | recruiting | — | 2,000 | Peking University First HospitalOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT05757219 | Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy | recruiting | Phase 2 | 27 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT05892393 | Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma | recruiting | Phase 1 | 20 | Robert Flavell, MD, PhDOTHER | 1 | Sep 16, 2026 | clinicaltrials |
Data updated 5 days agoSource updated Sep 21, 2026source: clinicaltrials